President Donald J. Trump’s executive order that allows HHS to cap certain prescription drug prices for Medicare to what he called the “most-favored-nation price” will be difficult to implement, experts said.
The executive order, signed Sept. 13, states that Medicare Part B and Part D drug prices will align with the lowest cost of a drug that is sold to any country in the Organisation for Economic Co-operation and Development that has a “comparable per-capita gross domestic product.”
Nancy Nielsen, MD, PhD, a former senior advisor at CMS and now senior associate
Uncategorized